Placental site trophoblastic tumor as a rare cause of irregular bleeding in a female of reproductive age

Objective: A case of placental site trophoblastic tumor (PSTT) that presented with abnormal vaginal bleeding is reported because of its rarity. Case report: The patient presented with 8 weeks of amenorrhea, vaginal bleeding and a persistently low titer of β-human chorionic gonadotropin (βhCG). A large circumscribed mass in the uterus was revealed by ultrasound and magnetic resonance imaging. Hysteroscopic biopsy confirmed the presence of PSTT and a hysterectomy was subsequently performed. The patient is well after 6 months of follow up and her βhCG titer normalized. Conclusion: Rare forms of trophoblastic disease should be considered in the differential diagnosis of persistent bleeding and low titers of βhCG.

Placental site trophoblastic tumor; Gestational trophoblastic disease; Trophoblastic tumor; Intermediate trophoblasts

[1] Horowitz N.S., Goldstein D.P., Berkowitz R.S.: “Placental site tro­ phoblastic tumors and epithelioid trophoblastic tumors: Biology, natural history, and treatment modalities”. Gynecol. Oncol., 2017, 144, 208.

[2] Papadopoulos A.J., Foskett M., Seckl M.J., McNeish I., Paradinas F.J., Rees H., Newlands E.S.: “Twenty­five years’ clinical expe­rience with placental site trophoblastic tumors”. J. Reprod. Med., 2002, 47, 460.

[3] Schmid P., Nagai Y., Agarwal R., Hancock B., Savage P.M., Se­bire N.J., et al.: “Prognostic markers and long­term outcome of placental­site trophoblastic tumours: a retrospective observational study”. Lancet, 2009, 374, 48.

[4] Kurman R.J., Scully R.E., Norris H.J. “Trophoblastic pseudotumor of the uterus: An exaggerated form of “syncytial endometritis” sim­ulating a malignant tumor”. Cancer, 1976, 38, 1214.

[5] Twiggs L.B., Okagaki T., Phillips G.L., Stroemer J.R., Adcock L.L.: “Trophoblastic pseudotumor­evidence of malignant disease poten­tial.” Gynecol. Oncol., 1981, 12, 238.

[6] Scully R.E., Young R.H.: “Trophoblastic pseudotumor: A reap­praisal”. Am. J. Surg. Pathol., 1981, 5, 75.

[7] Kohorn E.I.: “Long­term outcome of placental­site trophoblastic tu­mours”. Lancet, 2009, 374, 6.

[8] Feltmate C.M., Genest D.R., Wise L., Bernstein M.R., Goldstein D.P., Berkowitz R.S.: “Placental Site Trophoblastic Tumor: A 17­ Year Experience at the New England Trophoblastic Disease Center”. Gynecol. Oncol., 2001, 82, 415.

[9] Newlands E.S., Bower M., Fisher R.A., Paradinas F.J.: “Manage­ment of placental site trophoblastic tumors”. J. Reprod. Med., 1998, 43, 53.

[10] Zhao J., Lv W.G., Feng F.Z., Wan X.R., Liu J.H., Yi X.F., et al. “Pla­cental site trophoblastic tumor: A review of 108 cases and their im­plications for prognosis and treatment”. Gynecol Oncol, 2016, 142, 102.

[11] Kim S.J.: “Placental site trophoblastic tumour”. Best Practice Res. Clin. Obstet. Gynaecol., 2003, 17, 969.

[12] Chang Y.L., Chang T.C., Hsueh S., Huang K.G., Wang P.N., Liu H.P., Soong Y.K.: “Prognostic factors and treatment for placental site trophoblastic tumor­report of 3 cases and analysis of 88 cases”. Gynecol. Oncol., 1999, 73, 216.

[13] Newlands E.S., Mulholland P.J., Holden L., Seckl M.J., Rustin G.J.: “Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high­risk gestational tro­phoblastic tumors refractory to EMA/cyclophosphamide and vin­cristine chemotherapy and patients presenting with metastatic pla­cental site trophoblastic tumors”. J. Clin. Oncol., 2000, 18, 854.